HDFC Securities has come out with its third quarter (October-December) earnings estimates for the Pharmaceuticals sector. The brokerage house expects Alembic Pharma to report net profit at Rs 100 crore down 16.1% quarter-on-quarter.
Net Sales are expected to decrease by 9.5 percent Q-o-Q (down 14.2 percent Y-o-Y) to Rs 790 crore, according to HDFC Securities.
Earnings before interest, tax, depreciation and amortisation (EBITDA) are likely to fall by 12 percent Q-o-Q (down 59.3 percent Y-o-Y) to Rs 160 crore.
Disclaimer: The views and investment tips expressed by investment experts on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
